Thrush Medication

  • Author: Robert W Tolan Jr, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Jan 9, 2012
 

Medication Summary

Antifungal therapy generally hastens resolution of infection. The treatment of choice for thrush is oral nystatin suspension, although numerous antifungal agents are effective. Resistance to nystatin is rare, although the drug's contact killing makes it somewhat more difficult to use because it must be applied to all of the affected mucosal surfaces to be effective (unlike systemic therapies).

In older children and adults, antifungal medications should be swished around in the oral cavity and swallowed. Failure to do so may provide ineffective treatment for lesions in the posterior pharynx and esophagus. In younger patients, instruct parents to apply 1-2 mL of the solution to the inside of each cheek during each administration. Medication can also be directly applied to the lesions with a nonabsorbent swab or applicator. The best time to administer medication is between meals because this allows longer contact time.

Gentian violet solution should not be swallowed. Lozenges (troches) may be used if suspension preparations are unavailable.

These antifungal preparations have minimal adverse effects and few contraindications because they involve little or no systemic absorption. Aside from itraconazole, against which candidal resistance is increasing, other readily available antifungals are effective. If inability to adequately apply nystatin (or the oral cavity's normal flushing mechanisms) results in treatment failure, oral fluconazole or gentian violet are second-line agents.

Next

Antifungal agents

Class Summary

The mechanism of action may involve an alteration of RNA and DNA metabolism or an intracellular accumulation of peroxide that is toxic to the fungal cell.

View full drug information

Nystatin (Mycostatin, Nilstat, Nystex)

 

DOC for oral thrush. No significant absorption from the intact skin, GI tract, or vagina. Fungicidal and fungistatic antibiotic obtained from Streptomyces noursei; effective against various yeasts and yeastlike fungi. Changes permeability of fungal cell membrane after binding to cell membrane sterols, causing cellular contents to leak.

View full drug information

Amphotericin B deoxycholate (Fungizone Oral Suspension)

 

Produced by a strain of Streptomyces nodosus; can be fungistatic or fungicidal. Binds to sterols (eg, ergosterol) in the fungal cell membrane, causing intracellular components to leak with subsequent fungal cell death.

View full drug information

Clotrimazole (Mycelex Troches)

 

Alters cell membrane. Very effective treatment in immunocompetent host. If susp not available (not available in the United States), troches (lozenges) can be used, but troche has been associated with elevated liver enzymes and GI adverse effects.

View full drug information

Miconazole oral (Daktar)

 

Not available in the United States. Damages fungal cell wall membrane by inhibiting biosynthesis of ergosterol; increases membrane permeability, causing nutrients to leak out, resulting in fungal cell death.

Gentian violet

 

Although inexpensive, efficacious for thrush refractory to other therapies. Solution stains clothing and mucosa intensely, causing undesirable cosmetic effects.

View full drug information

Fluconazole (Diflucan)

 

Azole antifungal with excellent bioavailability. Interferes with cell membrane and is eliminated via renal pathway.

Fungistatic activity. Synthetic PO antifungal (broad-spectrum bistriazole) that selectively inhibits fungal CYP450 and sterol C-14 alpha-demethylation, which prevents conversion of lanosterol to ergosterol, thereby disrupting cellular membranes.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Coauthor(s)

Mudra Kumar, MD, MBBS, MRCP  Associate Professor, Department of Pediatrics, University of South Florida College of Medicine

Mudra Kumar, MD, MBBS, MRCP is a member of the following medical societies: American Academy of Pediatrics and American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Leonard R Krilov, MD  Chief of Pediatric Infectious Diseases and International Adoption, Vice Chair, Department of Pediatrics, Professor of Pediatrics, Winthrop University Hospital

Leonard R Krilov, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Medimmune Grant/research funds Cliinical trials; Medimmune Honoraria Speaking and teaching; Medimmune Consulting fee Consulting

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Leslie L Barton, MD  Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

References

  1. [Guideline] Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. Mar 1 2009;48(5):503-35. [Medline].

  2. Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J. Sep 1997;16(9):885-94. [Medline].

  3. Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol. Feb 2003;90(2):259-64. [Medline].

  4. Liu X, Hua H. Oral manifestation of chronic mucocutaneous candidiasis: seven case reports. J Oral Pathol Med. Oct 2007;36(9):528-32. [Medline].

  5. Rowen JL. Mucocutaneous candidiasis. Semin Perinatol. Oct 2003;27(5):406-13. [Medline].

  6. Raucher HS. Should we be treating oral thrush?. Pediatr Infect Dis J. Mar 1998;17(3):267. [Medline].

  7. [Best Evidence] Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005;CD003135. [Medline].

  8. Allen G, Logan R, Gue S. Oral manifestations of cancer treatment in children: a review of the literature. Clin J Oncol Nurs. Aug 2010;14(4):481-90. [Medline].

  9. Aytekin C, Dogu F, Tuygun N, Tanir G, Guloglu D, Boisson-Dupuis S, et al. Bacille Calmette-Guérin lymphadenitis and recurrent oral candidiasis in an infant with a new mutation leading to interleukin-12 receptor beta-1 deficiency. J Investig Allergol Clin Immunol. 2011;21(5):401-4. [Medline].

  10. Baley JE. Neonatal candidiasis: the current challenge. Clin Perinatol. Jun 1991;18(2):263-80. [Medline].

  11. Brown RS, Berg W, Schlesinger W, Childers EL. The CDx brush biopsy and the diagnosis of oral candidiasis. Dent Today. Aug 2007;26(8):96, 98-9. [Medline].

  12. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am. Jun 1988;35(3):543-63. [Medline].

  13. Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, Li RA, et al. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol. Jul 2011;4(4):448-55. [Medline]. [Full Text].

  14. Domaneschi C, Massarente DB, de Freitas RS, de Sousa Marques HH, Paula CR, Migliari DA, et al. Oral colonization by Candida species in AIDS pediatric patients. Oral Dis. May 2011;17(4):393-8. [Medline].

  15. dos Santos Pinheiro R, Franca TT, et al. Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. J Oral Pathol Med. Sep 2009;38(8):613-22. [Medline].

  16. Egusa H, Soysa NS, Ellepola AN, Yatani H, Samaranayake LP. Oral candidosis in HIV-infected patients. Curr HIV Res. Nov 2008;6(6):485-99. [Medline].

  17. Gonzalez Gravina H, Gonzalez de Moran E, Zambrano O, et al. Oral Candidiasis in children and adolescents with cancer. Identification of Candida spp. Med Oral Patol Oral Cir Bucal. Oct 2007;12(6):E419-23. [Medline].

  18. Grimm SE 3rd, Lawrence L, Bailey J, Brown RS. Oral thrush in a one-month old infant: etiology and treatment. Dent Today. Jun 2009;28(6):55-7; quiz 57. [Medline].

  19. Jones W, Breward S. Thrush and breastfeeding. Identifying and treating thrush in breastfeeding mothers and babies. Community Pract. Oct 2010;83(10):42-3. [Medline].

  20. Kumamoto CA, Vinces MD. Alternative Candida albicans lifestyles: growth on surfaces. Annu Rev Microbiol. 2005;59:113-33. [Medline].

  21. Kwon-Chung KJ, Bennett JE, eds. Medical Mycology. Philadelphia, Pa: Lea & Febiger; 1992:2288-301.

  22. Liguori G, Lucariello A, Colella G, De Luca A, Marinelli P. Rapid identification of Candida species in oral rinse solutions by PCR. J Clin Pathol. Sep 2007;60(9):1035-9. [Medline].

  23. Majorana A, Bardellini E, Flocchini P, Amadori F, Conti G, Campus G. Oral mucosal lesions in children from 0 to 12 years old: ten years' experience. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jul 2010;110(1):e13-8. [Medline].

  24. Marques SA. Fungal infections of the mucous membrane. Dermatol Ther. May-Jun 2010;23(3):243-50. [Medline].

  25. McCullough M, Patton LL, Coogan M, Fidel PL Jr, Komesu M, Ghannoum M, et al. New approaches to Candida and oral mycotic infections: Workshop 2A. Adv Dent Res. Apr 2011;23(1):152-8. [Medline].

  26. McGovern E, Fleming P, Costigan C, Dominguez M, Coleman DC, Nunn J. Oral health in Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED). Eur Arch Paediatr Dent. Dec 2008;9(4):236-44. [Medline].

  27. McManus BA, McGovern E, Moran GP, Healy CM, Nunn J, Fleming P, et al. Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence. J Clin Microbiol. May 2011;49(5):1879-89. [Medline]. [Full Text].

  28. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep. Feb 2008;5(1):5-12. [Medline].

  29. Noonan M, Leflein J, Corren J, Staudinger H. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. BMC Pediatr. Jul 13 2009;9:43. [Medline].

  30. Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses. Nov 2006;49(6):484-92. [Medline].

  31. Pankhurst C. Candidiasis (oropharyngeal). Clin Evid. Jun 2005;1701-16. [Medline].

  32. Perniola R, Congedo M, Rizzo A, et al. Innate and adaptive immunity in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Mycoses. May 2008;51(3):228-35. [Medline].

  33. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev. Nov 10 2010;11:CD003940. [Medline].

  34. Pomarico L, Cerqueira DF, de Araujo Soares RM, et al. Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Aug 2009;108(2):203-10. [Medline].

  35. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. Apr 1 2011;332(6025):65-8. [Medline]. [Full Text].

  36. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. Jul 2004;126(1):213-9. [Medline]. [Full Text].

  37. Russell C, Lay KM. Natural history of Candida species and yeasts in the oral cavities of infants. Arch Oral Biol. Aug 1973;18(8):957-62. [Medline].

  38. Segal BH, Steinbach WJ. Combination antifungals: an update. Expert Rev Anti Infect Ther. Oct 2007;5(5):883-92. [Medline].

  39. Shepherd J. Thrush and breastfeeding. Pract Midwife. Dec 2002;5(11):24-7. [Medline].

  40. Su CW, Gaskie S, Jamieson B, Triezenberg D. Clinical inquiries. What is the best treatment for oral thrush in healthy infants?. J Fam Pract. Jul 2008;57(7):484-5. [Medline].

  41. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 7th ed. 2000.

  42. Terai H, Shimahara M. Tongue pain: burning mouth syndrome vs Candida- associated lesion. Oral Dis. Jul 2007;13(4):440-2. [Medline].

  43. Vazquez JA. Posaconazole for the management of mucosal candidiasis. Future Microbiol. Jun 2007;2:245-56. [Medline].

  44. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am. Dec 2002;16(4):793-820, v. [Medline].

 
Previous
Next
 
White plaques are present on the buccal mucosa and the undersurface of the tongue and represent thrush. When wiped off, the plaques leave red erosive areas. Courtesy of Matthew C. Lambiase, DO.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.